SICHUAN ENWEI PHARMACY CO., LTD.

1. Main study objectives: To study the pharmacokinetics of the test preparation Alagoc sodium tablets (specification: 0.2g, produced by Sichuan Enwei Pharmaceutical Co., Ltd.) and the reference preparation Alagoc sodium tablets (trade name Orilissa®, specification: 0.2g; produced by AbbVie Inc.) in healthy subjects after single oral administration in fasting and fed state, and to evaluate the bioequivalence of the two preparations in fasting and fed state. 2. Secondary study objectives: To evaluate the safety of the test preparation Alagoc sodium tablets (specification: 0.2g) and the reference preparation Orilissa® (specification: 0.2g) in healthy subjects.

To further evaluate the clinical efficacy and safety of Danlong Tablets in the treatment of breast hyperplasia (Qi stagnation and blood stasis syndrome)